Government of Saskatchewan ministries, Crown corporations and organizations are implementing contingency plans to minimize the impacts of postal service disruption.
Les ministères, sociétés d’État et organismes du gouvernement de la Saskatchewan mettent en œuvre des plans d’urgence (en anglais) visant à réduire les répercussions de l’interruption du service des postes.
Google Translate Disclaimer
A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:
Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.
Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).
Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.
Released on March 17, 2022
Two new medications for treating Spinal Muscular Atrophy (SMA) are now covered in Saskatchewan. Zolgensma and Evrysdi are covered through the Drug Plan as eligible benefits for patients who meet certain medical criteria.
"Early diagnosis and treatment are crucial for better outcomes for patients with SMA," Health Minister Paul Merriman said. "The availability in Saskatchewan of newborn screening along with these cutting-edge medications will greatly improve the prognosis and quality of life for patients born with SMA and their families."
Zolgensma (onasemnogene abeparvovec) is a high-cost gene therapy for the treatment of pediatric patients that targets the underlying genetic defect in SMA by delivering a fully functional copy of the gene into the patient's appropriate cells. It is administered as an intravenous infusion, as a single lifetime dose. Evrysdi (risdiplam) is the first oral drug available to treat SMA. It works by increasing the protein that is deficient in SMA patients.
Spinraza, another drug for the treatment of SMA, is also covered under the Saskatchewan Formulary for patients who meet eligibility criteria.
Spinal Muscular Atrophy is a rare neuromuscular disorder caused by a genetic defect that can lead to impaired mobility, swallowing and breathing, and may result in early death. SMA is the number one genetic cause of infant mortality and it occurs in one in 10,000 babies born. Prior to availability of drug therapies, SMA had been managed by supportive care interventions that did not improve survival, motor development or progression of symptoms.
Treatments for SMA are more likely to be effective if introduced early in the course of the disease. Saskatchewan recently expanded its Universal Newborn Screening Program to include SMA. The program enables families to receive much earlier diagnosis and treatment.
Patients or caregivers who think they may benefit from these new medications are encouraged to speak with their physician regarding treatment options.
-30-
For more information, contact:
HealthWe need your feedback to improve saskatchewan.ca. Help us improve
